An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes

20248 citationsJournal Articlegold Open Access

Authors

These preclinical outcomes position AKS-107 for clinical development in T1D prevention settings.

Good health and well-being

Published in: Frontiers in Immunology

Volume 15, pp. 1367514-1367514

Field-Weighted Citation Impact: 4.61